A Fluorescence-based Assay Benefitting PROTAC Drug Discovery and Development

Back to all technologies
Download as PDF
Researchers at Purdue University have developed a fluorescence polarization (FP)-based activity assay to monitor tight binders to the substrate recognition domain of a family of E3 ligases. The design of proteolysis targeting chimeras (PROTACs) has so far relied on a limited amount of well-characterized E3 ligases. Most of these ligases are either cytosolic or nuclear in their cellular distribution.

By targeting membrane-bound proteins for their assay, researchers at Purdue University have opened new paths to the discovery and development of therapeutics. This assay can be used to screen for binders, which would open new avenues in the PROTAC field (i.e., utilization of novel E3 ligases). The FP-based assay is reproducible, and specific. Further, the assay may have other uses such as deubiquitinating enzyme (DUB) identification. The identification of DUBs in and of itself, presents new targets for drug discovery and development.

Technology Validation: Fluorescence Polarization was used to monitor ubiquitination of the peptide. Ubiquitination was confirmed via SDS-PAGE. Upon the addition of DUB, deubiquitination occurred, as shown by decreased FP. Deubiquitination was also confirmed by SDS-PAGE.

-Screen binders of novel E3 ligases
-Reproducible and selective
-Assay can also be used to screen for DUBs

- Drug development
- Drug discovery
Dec 16, 2022
United States
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org